Pre-made Elezanumab benchmark antibody ( Whole mAb, anti-RGMA therapeutic antibody, Anti-RGM Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-169-1mg	1mg	3090
GMP-Bios-ab-169-10mg	10mg	Inquiry
GMP-Bios-ab-169-100mg	100mg	Inquiry
GMP-Bios-ab-169-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody
INN Name	Elezanumab
Target	RGMA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	AbbVie
Conditions Approved	na
Conditions Active	Multiple sclerosis;Spinal cord injuries;Stroke
Conditions Discontinued	na
Development Tech	na